KTTA Pasithea Therapeutics Corp.
$0.53▼ -1.85%
Healthcare
Other
After hours
$0.53▲ +0.00%
Sep 11, 5:25 PM ET
Volume 141.7K
Avg Volume (10D) 258.9K
Key Metrics & Fundamentals
Market Cap
$17.71M
P/E Ratio
–
Div Yield
–%
52W Range
0.28 - 2.06
% vs 50 MA
5.68%
% vs 200 MA
-28.47%
RSI-14
48.7
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.46
Free Cash Flow
-$4.71M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$5.55M
COGS
–
Operating Exp
$5.71M
Operating Income
-$5.71M
EBIT
-$5.71M
Pretax Income
-$5.27M
Net Income
-$5.27M
EPS (Diluted)
-0.16
Price & Volume History
Loading chart…
Recent News
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
GlobeNewswire · Sep 14, 2026 11:00 AM
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
GlobeNewswire · Sep 3, 2026 8:05 PM
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
GlobeNewswire · Jul 8, 2026 11:02 AM
Pasithea Therapeutics Says Interim Phase 1 Data for PAS-004 Show Durable Clinical Activity
MT Newswires · Jun 30, 2026 12:19 PM
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
GlobeNewswire · Jun 30, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See KTTA's money flow as a full page
Social Sentiment
No Reddit posts found for KTTA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.